BridgeLine Translational
Strategy for biotech, investors, and partners.
The firm advises on competitive intelligence, portfolio and indication strategy, preclinical development, and investor and partner readiness.
01 / Capabilities
Capabilities
Every engagement runs on the same discipline: a close read of the science behind the programs. Work can be scoped to a single capability or combined across several, depending on what you need.
Three buyer scenarios under one capability: buy-side diligence on a target company, target evaluation, and competitive landscape for a program.
Choose the right indication for a therapeutic, allocate across multiple programs, or pick where a platform should deploy first.
Study-by-study IND plan with model selection, endpoints, go/no-go gates, timelines, and budgets.
Independent analysis of the package investors and partners will see. Narrative review, data room structure, readiness scorecard, gap register, and written advice on what to fix.
02 / The practice
The practice.
BridgeLine reads the evidence behind biotech programs. Primary sources, protocol-level analysis, candid written output.
i
Protocol-level evaluation
BridgeLine reads at the protocol level: tox package adequacy, dose rationale, species choice, biodistribution fit, endpoint translatability, formulation risk.
ii
Modality-specific depth
AAV capsid selection, LNP formulation, base-editing off-target analysis, oligonucleotide delivery, covered at protocol level.
iii
Source-traced by default
Every claim in a BridgeLine deliverable links to primary evidence: a filing, a trial record, a paper, a label. Claims can be checked against source and cited in investor and partner conversations.
iv
Single-principal engagement
Scope, analysis, and review sit with one principal. Written output names strengths and weaknesses.
03 / Inside the work
From scoping call to source-traced deliverable.
Engagements run in three phases. Scope is defined in writing before work begins.
01 / Phase
Scoping call
Thirty minutes. The engagement surface, competitor set, and modality are confirmed. A written SOW follows.
02 / Phase
Evidence and evaluation
Primary-source retrieval (FDA, ClinicalTrials.gov, SEC, PubMed, agency press). Each competitor's program read scientifically. Every claim linked to its source. Weak points flagged explicitly.
03 / Phase
Delivery and debrief
A source-traced document and a verbal debrief. Open questions named. If the engagement points toward a follow-on (Preclinical Strategy, Investor/Partner Readiness), that scope is offered separately.
04 / Selected work
Selected case work.
Anonymized engagements.
Rare kidney indication, no clear development path.
A research team had proof-of-principle data and no development plan. The roadmap that came out of the engagement cut 14 months from the projected timeline.
Outcome
14 months cut from projected timeline
RNA platform indication prioritization.
An RNA platform with 30-plus candidate indications and no structured way to choose. A scoring framework narrowed the field to three, with the rationale written down for the team to reuse.
Read the full case study06 / Results in practice
Cut from a gene therapy IND timeline through structured roadmap planning.
Read case studyIn study costs preserved by go/no-go gates in a biologics engagement.
Read case studyCandidate indications narrowed with a scoring framework that became the team's standing tool.
Read case study07 / Contact
BridgeLine Translational.
A remote practice serving biotech clients worldwide. info@bridgelinetranslational.com.
Schedule a call